Hims & Hers Surges 41% on Landmark GLP-1 Supply Deal with Novo Nordisk
Key Takeaways
- Hims & Hers Health shares skyrocketed 41% following a strategic agreement with Novo Nordisk to distribute branded GLP-1 medications, including Ozempic, directly through its telehealth platform.
- The deal effectively ends a high-stakes patent dispute and transitions the company away from controversial compounded formulations toward FDA-approved branded therapies.
Mentioned
Key Intelligence
Key Facts
- 1Hims & Hers stock surged 40.72% to close at $22.15 on March 9, 2026.
- 2Novo Nordisk dropped its patent infringement lawsuit against Hims & Hers as part of the collaboration.
- 3Hims & Hers will transition from selling compounded GLP-1s to branded Ozempic on its platform.
- 4Trading volume for HIMS reached 168.1 million shares, 557% above its three-month average.
- 5Needham and Citi raised their price targets for HIMS to $30 and $24, respectively.
| Company | |||
|---|---|---|---|
| Hims & Hers Health | HIMS | +40.72% | $22.15 |
| Teladoc Health | TDOC | +4.33% | $5.30 |
| American Well | AMWL | +1.65% | $5.55 |
| Novo Nordisk | NVO | +3.00% | N/A |
Analysis
Hims & Hers Health (HIMS) experienced a historic trading session on March 9, with shares closing up 40.72% at $22.15. The catalyst was a transformative collaboration with pharmaceutical giant Novo Nordisk (NVO) to sell branded GLP-1 weight-loss medications. This move represents a fundamental pivot for the direct-to-consumer telehealth platform, which had previously relied on compounded versions of these drugs to meet surging consumer demand. The market's reaction was emphatic, with trading volume reaching 168.1 million shares—a staggering 557% increase over its three-month average of 25.6 million shares. This surge underscores investor relief that the company has secured a legitimate, long-term path into the lucrative weight-loss market.
Perhaps the most significant aspect of the deal is the resolution of a major legal overhang. Novo Nordisk agreed to drop its patent infringement lawsuit against Hims & Hers as part of the agreement. In exchange, Hims & Hers will cease the marketing and sale of compounded GLP-1 formulations, which have been a point of contention between telehealth providers and pharmaceutical manufacturers. This transition to FDA-approved branded medications like Ozempic provides Hims & Hers with a level of regulatory legitimacy and long-term stability that was previously missing from its weight-loss segment. By aligning with the primary manufacturer, Hims & Hers has effectively traded the higher margins of compounded drugs for the lower-risk, high-volume potential of branded distribution.
Analysts at Needham and Citi were quick to respond, raising their price targets to $30 and $24, respectively.
While Hims & Hers led the sector, the news lifted other telehealth names as well, though to a lesser degree. Teladoc Health (TDOC) rose 4.33% and American Well (AMWL) gained 1.65%. The disparity in gains suggests that investors view Hims & Hers as the primary beneficiary of the GLP-1 "gold rush," particularly given its ability to secure a direct partnership with the primary manufacturer. Analysts at Needham and Citi were quick to respond, raising their price targets to $30 and $24, respectively. They noted that while the shift to branded drugs might impact near-term margins compared to higher-margin compounded versions, the reduction in legal risk and the potential for massive volume growth more than compensate for the change.
What to Watch
Despite the massive single-day gain, Hims & Hers remains approximately 62% below its 52-week high, suggesting further room for recovery as the market digests the implications of this partnership. Trading at roughly 20 times forward earnings, the stock's risk-reward profile has shifted dramatically. By securing a reliable supply of branded GLP-1s, Hims & Hers has effectively de-risked its most promising growth engine. The company, which has grown 126% since its 2019 IPO, is now positioned as a legitimate, large-scale distributor for the most sought-after medications in the modern pharmaceutical landscape. This deal removes what was arguably the biggest headwind facing the stock: the threat of regulatory or legal shutdown of its compounding operations.
Moving forward, the industry will be watching how Hims & Hers manages the transition of its existing customer base from compounded products to branded Ozempic. The success of this partnership could serve as a blueprint for other telehealth companies looking to move away from the "grey market" of compounding and into formal distribution agreements with Big Pharma. For Novo Nordisk, the deal provides a high-efficiency digital channel to reach consumers directly, bypassing traditional brick-and-mortar pharmacy friction. This hybrid model—combining digital health platforms with established pharmaceutical supply chains—is likely to become the new standard for chronic weight management and metabolic health, offering a more scalable solution to the global obesity crisis.